BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 03/08/2023

FDA Clears Path for K-TAB Extended-Release Tablets

The FDA has determined that K-TAB extended-release tablets, 10 milliequivalents and 20 milliequivalents, were not withdrawn from sale due to safety or effectiveness concerns, paving the way for approval of abbreviated new drug applications for these formulations.

Source: Federal Register — Food and Drug AdministrationOpen original release →